Ribavirin: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Jamie Costa (talk | contribs) No edit summary |
Jamie Costa (talk | contribs) No edit summary |
||
| Line 22: | Line 22: | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
# Gish, R. G | # Gish, R. G. Treating HCV with ribavirin analogue and ribavirin-like molecules. Journal of Antimicrobial Chemotherapy. 2005, November 17; 1-6. doi:10.1093/jac/dki405 | ||
# Chung, R.T., Gale, M.J., Polyak, S.J., Lemon, S.M., Liang, T.J., & Hoofnagle, J.H | # Chung, R.T., Gale, M.J., Polyak, S.J., Lemon, S.M., Liang, T.J., & Hoofnagle, J.H. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology, 2008; 47 (1), 306-320. doi: 10.1002/hep.22070 | ||
# Paeshuyse, J, Dallmeier, K, Neyts, J | # Paeshuyse, J, Dallmeier, K, Neyts, J. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Current Opinion in Virology.2011; 1(6): 590-598. doi: 10.1016/j.coviro.2011.10.030 | ||
# National Heart, Lung and Blood Institute. | # National Heart, Lung and Blood Institute. Pneumonia. 2016, September 26; Retrieved from https://www.nhlbi.nih.gov/health/health-topics/topics/pnu | ||
# Foster, G. | # Foster, G. Pegylated interferons for the treatment of chronic Hepatitis C. Drugs. 2010;70(2):147-165. doi:10.2165/11531990-000000000-00000 | ||
